Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Patients are being asked to participate in this study who have locally advanced or metastatic
pancreatic cancer (cancer of the pancreas that has spread to another part of the body) that
has gotten worse after first-line chemotherapy.
The purpose of this study is to see if the drugs, Capecitabine and Lapatinib (two
chemotherapy agents), prolong survival and improve quality of life as compared to supportive
care alone.
Lapatinib in combination with a drug called capecitabine, has been approved by the Food and
Drug Administration (FDA) for the treatment of metastatic breast cancer. It has not yet been
approved to treat this type of cancer. Both of these drugs are pills.
This research is being done because it is not known if the combination of Capecitabine and
Lapatinib is better than supportive care alone for pancreatic cancer.